Uncategorized Archives | MPM BioImpact

29th January 2025

Cullinan Therapeutics Announces Primary Endpoint Met in Phase 2b Trial of Zipalertinib

8th January 2025

MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner

8th January 2025

MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner

7th January 2025

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)